This announcement is a separate document:
Argenica Therapeutics Ltd: First Patient Dosed in Phase 2 Stroke Trial of ARG-007
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.